Skip to main content
Clinical Trials/EUCTR2012-001260-29-IT
EUCTR2012-001260-29-IT
Active, not recruiting
Not Applicable

Identification of predictive plasma Biomarkers and use of a high dosage statin during a procedure of Parrossistic Atrial Fibrillation pharmacological Cardioversion - 2012-CARDAF

FONDAZIONE ISTITUTO SAN RAFFAELE-G.GIGLIO0 sitesMarch 29, 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
FONDAZIONE ISTITUTO SAN RAFFAELE-G.GIGLIO
Status
Active, not recruiting
Last Updated
13 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 29, 2012
End Date
TBD
Last Updated
13 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
FONDAZIONE ISTITUTO SAN RAFFAELE-G.GIGLIO

Eligibility Criteria

Inclusion Criteria

  • 1\) patient between 18 and 75 years of age 2\) patient able to understand the study aims and methods, to sign the informed consents relative to the part of the study he is willing to participate 3\) patient showing the medical conditions that make a cardioversion procedure mandatory 4\) patient whose clinical conditions allow to delay the cardioversion procedure for the time required to enroll the patients in the study (stable patient, that is not feeling extreme pain or anxiety for the condition related to the current episode of atrial fibrillation)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 120
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 120

Exclusion Criteria

  • 1\) hemodynamically unstable patient or bearing comorbidities precluding the possibility to complete the procedures of the study. 2\) patient with diagnosis of class III\-IV heart failure according to the NYHA classification 3\) patients assuming chronically a statin at maximum dosage. 4\) patient without hystory of statin intollerance characterized by: statin related myalgia and/or increase of specific enzymes elevation (CK \> 2xULN; AST or ALT \> 3x ULN) 5\) patient assuming oral anticoagulant therapy 6\) patient with affections determining intestinal malabsorption as: gastro\-ileal by pass, gastric banding, other causes 7\) patient with chronic kidney disease stage IV or more according to the NFK classification (calculated Glomerular filtrate rate \< 30 ml/min) 8\) patient with altered consciousness level, and/or a mental disease not adequately controlled by drug therapy.

Outcomes

Primary Outcomes

Not specified

Similar Trials